Analysis of clinical characteristics and outcomes of ALK positive (ALK plus ) patients treated with ALK inhibitors (ALKi).

被引：0

作者：

Perez, Susana Cedres

Aranda, Nuria Pardo

Navarro, Alejandro

Marti, Alex Martinez

de Castro, Ana Maria Martinez

Cabrera, Guadalupe

Vilaro, Marta

Carbonell, LLuisa

de la Fuente, Iris

Piera, Adelaida

Martinez, Lidia

Hernandez-Losa, Javier

Sansano, Irene

Felip, Enriqueta

机构：

[1] Vall dHebron Univ Hosp, Barcelona, Spain

[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain

[3] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[4] Inst Salvadoreno Seguro Social, San Salvador, El Salvador

[5] Vall dHebron Inst Oncol, Oncol Data Sci OdysSey Grp, Barcelona, Spain

[6] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain

[7] Vall dHebron Univ, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.e20550

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e20550

引用

页数：2

共 50 条

[31] Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
Takeyasu, Yuki
Okuma, Hitomi S.
Kojima, Yuki
Nishikawa, Tadaaki
Tanioka, Maki
Sudo, Kazuki
Shimoi, Tatsunori
Noguchi, Emi
Arakawa, Ayumu
Mori, Taisuke
Sunami, Kuniko
Kubo, Takashi
Kohno, Takashi
Akihiko, Yoshida
Yamamoto, Noboru
Yonemori, Kan
JCO PRECISION ONCOLOGY, 2021, 5 : 756 - 766
[32] B and CTL responses to the ALK protein in patients with ALK-positive ALCL
Ait-Taharl, K
Cerundolo, V
Banham, AH
Hatton, C
Blanchard, T
Kusec, R
Becker, M
Smith, GL
Pulford, K
INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (03) : 688 - 695
[33] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Chang, Gee-Chen
Yang, Tsung-Ying
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Huang, Yen-Hsiang
Su, Kang-Yi
Yu, Sung-Liang
Tseng, Jeng-Sen
SCIENTIFIC REPORTS, 2020, 10 (01)
[34] Survival outcomes in ALK-positive NSCLC patients (p) treated 1st line brigatinib and impact of the ALK fusion variant
Provencio-Pulla, Mariano
Campelo, Rosario Garcia
Azkarate, Aitor
Calvo, Virginia
Cobo, Manuel
Mosquera, Joaquin
Nadal, Ernest
Rodriguez-Abreu, Delvys
Fabregat, Raquel Marse
Callejo, Ana
Domine, Manuel
Juan-Vidal, Oscar
Garcia-Garcia, Francisco
Sanchez, Estela
Romero, Atocha
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[35] ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Gee-Chen Chang
Tsung-Ying Yang
Kun-Chieh Chen
Kuo-Hsuan Hsu
Yen-Hsiang Huang
Kang-Yi Su
Sung-Liang Yu
Jeng-Sen Tseng
Scientific Reports, 10
[36] Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients
Davis, Keith L.
Kaye, James A.
Iyer, Shrividya
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S412
[37] Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer
Costa, Daniel B.
TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 373 - 375
[38] Effective Use of ALK Inhibitors in EML4::ALK-Positive Lymphatic Malformations
Apsel Winger, Beth
Dowd, Christopher F.
Shimano, Kristin A.
Devine, W. Patrick
Mathes, Erin
Frieden, Ilona
Schaefer, Carrie
Kothari, Alok
PEDIATRIC BLOOD & CANCER, 2024,
[39] Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
Isozaki, Hideko
Takigawa, Nagio
Kiura, Katsuyuki
CANCERS, 2015, 7 (02) : 763 - 783
[40] PLCXD3-ALK, a novel ALK rearrangement in lung squamous cell carcinoma and its clinical responses to ALK inhibitors
Chen, Kaidi
Chen, Xiuqiong
Wang, Xinyue
Yan, Bing
Liu, Aiqin
Wang, Youhui
Zhou, Jing
Wei, Qianhui
Pan, Yi
Jiang, Richeng
JOURNAL OF THORACIC DISEASE, 2025, 17 (01) : 93 - 108

← 1 2 3 4 5 →